Announcement • Apr 17
Evonik Industries AG, Annual General Meeting, Jun 03, 2026 Evonik Industries AG, Annual General Meeting, Jun 03, 2026, at 10:00 W. Europe Standard Time. Announcement • Feb 06
Evonik Industries AG announces Annual dividend, payable on June 08, 2026 Evonik Industries AG announced Annual dividend of EUR 1.0000 per share payable on June 08, 2026, ex-date on June 04, 2026 and record date on June 05, 2026. Announcement • Oct 06
Evonik Industries AG to Report Q4, 2025 Results on Mar 04, 2026 Evonik Industries AG announced that they will report Q4, 2025 results on Mar 04, 2026 Announcement • Sep 26
Evonik Industries AG Provides Earnings Guidance for the Third Quarter of 2025 Evonik Industries AG provided earnings guidance for the third quarter of 2025. The company expects revenue to be around €3.4 billion in the third quarter of 2025, compared to €3.8 billion in third quarter of 2024. Announcement • Mar 06
Evonik Industries AG announces Annual dividend, payable on June 02, 2025 Evonik Industries AG announced Annual dividend of EUR 1.1700 per share payable on June 02, 2025, ex-date on May 29, 2025 and record date on May 30, 2025. Announcement • Sep 20
Evonik Industries AG to Report Q1, 2025 Results on May 12, 2025 Evonik Industries AG announced that they will report Q1, 2025 results on May 12, 2025 Reported Earnings • May 10
First quarter 2024 earnings released: EPS: €0.33 (vs €0.10 in 1Q 2023) First quarter 2024 results: EPS: €0.33 (up from €0.10 in 1Q 2023). Revenue: €3.80b (down 5.2% from 1Q 2023). Net income: €156.0m (up 232% from 1Q 2023). Profit margin: 4.1% (up from 1.2% in 1Q 2023). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 2.7% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance. Announcement • Mar 05
International Chemical Investors S.E. agreed to acquire Superabsorbents business of Evonik. International Chemical Investors S.E. agreed to acquire Superabsorbents business of Evonik on March 4, 2024. The business to be sold generated sales of €892 million in 2023, with adjusted EBITDA in the mid double-digit million euro range. The final transfer of the business is planned for mid-2024 following approval by the relevant competition authorities. Announcement • Jan 16
Lanxess Reportedly Seeks to Sell Polyurethane Ops LANXESS Aktiengesellschaft (XTRA:LXS) has initiated a process to sell its polyurethane business, which could be valued at between EUR 500 million (USD 547.2 million) and EUR 600 million, German paper Handelsblatt reported on January 15, 2024. The company has engaged Deutsche Bank to search for a buyer, Handelsblatt said, citing people familiar with the matter. Chemical companies such as Evonik Industries AG (XTRA:EVK), Stockmeier, or Plixxent, are considered possible interested parties. With the sale, Lanxess aims to completely exit the plastics market as the company has transformed into a producer of ingredients for food, cosmetics, and pharmaceuticals. Reported Earnings • Nov 08
Third quarter 2023 earnings released: €0.21 loss per share (vs €0.46 profit in 3Q 2022) Third quarter 2023 results: €0.21 loss per share (down from €0.46 profit in 3Q 2022). Revenue: €3.77b (down 23% from 3Q 2022). Net loss: €96.0m (down 145% from profit in 3Q 2022). Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 5.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Announcement • Jul 12
Evonik Industries AG Revises Financial Guidance for the Full Year 2023 Evonik Industries AG revised financial guidance for the full year 2023. The sales outlook is adjusted to a range between EUR 14 billion and EUR 16 billion (previously: EUR 17 billion to EUR 19 billion). Announcement • Jun 09
RAG Stiftung Not in Hurry to Cut Evonik Stake RAG-Stiftung is not in a hurry to reduce its stake in chemicals firm Evonik Industries AG (XTRA:EVK) as the foundation is not under financial pressure, RAG chairman Bernd Toenjes said at a press conference as quotes by German paper Frankfurter Allgemeine Zeitung (FAZ). RAG Stiftung, which owns 54.9% in the chemicals company, plans to cut its stake to a blocking minority in the future. The shareholding may fall below the majority threshold soon. According to Toenjes, a convertible bond is due in 2024, providing an opportunity to reach 50% by the end of 2024. For the moment, Evonik remains one of the most important assets for RAG Stiftung. Upcoming Dividend • May 25
Upcoming dividend of €1.17 per share at 5.8% yield Eligible shareholders must have bought the stock before 01 June 2023. Payment date: 05 June 2023. The company is paying out more than 100% of its profits and is paying out 81% of its cash flow. Trailing yield: 5.8%. Within top quartile of British dividend payers (5.8%). Higher than average of industry peers (2.5%). Reported Earnings • May 10
First quarter 2023 earnings released: EPS: €0.10 (vs €0.67 in 1Q 2022) First quarter 2023 results: EPS: €0.10 (down from €0.67 in 1Q 2022). Revenue: €4.01b (down 11% from 1Q 2022). Net income: €47.0m (down 85% from 1Q 2022). Profit margin: 1.2% (down from 7.0% in 1Q 2022). Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has fallen by 3% per year. Reported Earnings • Mar 03
Full year 2022 earnings released: EPS: €1.16 (vs €1.61 in FY 2021) Full year 2022 results: EPS: €1.16 (down from €1.61 in FY 2021). Revenue: €18.5b (up 24% from FY 2021). Net income: €539.0m (down 28% from FY 2021). Profit margin: 2.9% (down from 5.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.6% p.a. on average during the next 3 years, compared to a 1.3% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 11
Second quarter 2022 earnings released: EPS: €0.64 (vs €0.48 in 2Q 2021) Second quarter 2022 results: EPS: €0.64 (up from €0.48 in 2Q 2021). Revenue: €4.77b (up 31% from 2Q 2021). Net income: €297.0m (up 34% from 2Q 2021). Profit margin: 6.2% (up from 6.1% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is expected to shrink by 1.9% compared to a 21% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Upcoming Dividend • May 19
Upcoming dividend of €1.17 per share Eligible shareholders must have bought the stock before 26 May 2022. Payment date: 31 May 2022. Payout ratio is a comfortable 63% and this is well supported by cash flows. Trailing yield: 4.5%. Lower than top quartile of British dividend payers (4.8%). Higher than average of industry peers (2.8%). Reported Earnings • May 07
First quarter 2022 earnings released: EPS: €0.67 (vs €0.41 in 1Q 2021) First quarter 2022 results: EPS: €0.67 (up from €0.41 in 1Q 2021). Revenue: €4.50b (up 34% from 1Q 2021). Net income: €314.0m (up 63% from 1Q 2021). Profit margin: 7.0% (up from 5.7% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 2.1% compared to a 17% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 05
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: €1.61 (up from €1.05 in FY 2020). Revenue: €15.0b (up 23% from FY 2020). Net income: €748.0m (up 53% from FY 2020). Profit margin: 5.0% (up from 4.0% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.1%. Over the next year, revenue is forecast to grow 2.9% compared to a 10% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 1% per year. Announcement • Mar 04
Evonik Industries AG to Report Q4, 2022 Results on Mar 02, 2023 Evonik Industries AG announced that they will report Q4, 2022 results on Mar 02, 2023 Reported Earnings • Nov 06
Third quarter 2021 earnings released: EPS €0.49 (vs €0.32 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €3.87b (up 33% from 3Q 2020). Net income: €231.0m (up 55% from 3Q 2020). Profit margin: 6.0% (up from 5.1% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Reported Earnings • Aug 06
Second quarter 2021 earnings released: EPS €0.48 (vs €0.26 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €3.64b (up 29% from 2Q 2020). Net income: €221.0m (up 77% from 2Q 2020). Profit margin: 6.1% (up from 4.4% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Upcoming Dividend • May 27
Upcoming dividend of €1.15 per share Eligible shareholders must have bought the stock before 03 June 2021. Payment date: 08 June 2021. Trailing yield: 3.9%. Lower than top quartile of British dividend payers (4.1%). Higher than average of industry peers (1.5%). Reported Earnings • May 08
First quarter 2021 earnings released: EPS €0.41 (vs €0.29 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €3.36b (up 3.5% from 1Q 2020). Net income: €193.0m (up 42% from 1Q 2020). Profit margin: 5.7% (up from 4.2% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Reported Earnings • Mar 05
Full year 2020 earnings released The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: €12.2b (down 6.9% from FY 2019). Net income: €489.0m (down 35% from FY 2019). Profit margin: 4.0% (down from 5.7% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Analyst Estimate Surprise Post Earnings • Mar 05
Revenue beats expectations Revenue exceeded analyst estimates by 0.3%. Over the next year, revenue is forecast to grow 5.8% compared to a 8.0% decline forecast for the Chemicals industry in the United Kingdom. Is New 90 Day High Low • Feb 23
New 90-day high: €28.17 The company is up 12% from its price of €25.09 on 24 November 2020. The British market is up 7.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €50.81 per share. Is New 90 Day High Low • Jan 28
New 90-day high: €27.39 The company is up 32% from its price of €20.81 on 30 October 2020. The British market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €50.93 per share. Is New 90 Day High Low • Jan 06
New 90-day high: €27.24 The company is up 16% from its price of €23.51 on 08 October 2020. The British market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €51.28 per share. Is New 90 Day High Low • Dec 17
New 90-day high: €26.92 The company is up 16% from its price of €23.22 on 18 September 2020. The British market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €46.60 per share. Is New 90 Day High Low • Dec 01
New 90-day high: €25.75 The company is up 8.0% from its price of €23.74 on 02 September 2020. The British market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €38.09 per share. 
